Share on StockTwits
 

Cytokinetics (NASDAQ:CYTK) issued its quarterly earnings data on Thursday. The company reported $0.21 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.08) by $0.29, American Banking & Market News reports. The company had revenue of $24.30 million for the quarter, compared to the consensus estimate of $19.14 million.

Shares of Cytokinetics (NASDAQ:CYTK) traded up 0.73% during mid-day trading on Thursday, hitting $6.90. The stock had a trading volume of 399,182 shares. Cytokinetics has a 52 week low of $5.76 and a 52 week high of $14.28. The stock has a 50-day moving average of $7.74 and a 200-day moving average of $8.10. The company’s market cap is $203.6 million.

Cytokinetics, Incorporated (NASDAQ:CYTK) is a biopharmaceutical company focused on the discovery and development of small molecule therapeutics that modulate muscle function for the potential treatment of serious diseases and medical conditions.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.